|本期目录/Table of Contents|





The research progress of PCDH20 associated with malignant tumor
石文文1;?支园园1;?成秉林2;?郭林顿3;?成 浩4;?张淑君1
1.哈尔滨医科大学附属第四医院病理科,黑龙江 哈尔滨 150001;2.哈尔滨医科大学附属第一医院中西医结合科,黑龙江 哈尔滨 150001;3.哈尔滨医科大学(大庆校区)医学检验与技术学院,黑龙江 哈尔滨 163319;4.哈尔滨医科大学基础医学院,黑龙江 哈尔滨 150081
Shi Wenwen1;?Zhi Yuanyuan1;?Cheng Binglin2;?Guo Lindun3;?Cheng Hao4;?Zhang Shujun1
1.Department of Pathology,the Fourth Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China;2.Department of Integrated Tradition Chinese and Western Medicine Oncology,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China;3.College of Medical Laboratory and Technology,Harbin Medical University(Daqing),Heilongjiang Harbin 163319,China;4.Basic Medical College,Harbin Medical University,Heilongjiang Harbin 150081,China.
PCDH20;?diagnosis;?malignant tumor
Protocadherin 20 (PCDH20) is a transmembrane protein with pro-homologous antigen-binding activity,and it is one of the components of procalmodulin family.Studies have found that its coding gene exists on chromosome 13q21.PCDH20 participates in the growth and development of the nervous system and spinal dorsal horn of bone cancer pain excitatory synapse formation,and can involve in cancer development through a variety of mechanisms.Preliminary research results prove that it can serve as a wide variety of tumor suppressor genes,and in hepatocellular carcinoma,laryngeal squamous carcinoma and others plays a very important significance in development and incidence of malignant tumors.It is expected to provide new ideas and plans for the diagnosis and treatment of tumors.In this paper,the recent progress of PCDH20 in malignant tumor is reviewed.


[1] Lv J,Zhu P,Yang Z,et al.PCDH20 functions as a tumour-suppressor gene through antagonizing the Wnt/β-catenin signalling pathway in hepatocellular carcinoma[J].Journal of Viral Hepatitis,2015,22(2):201-211.
[2]Chapman NH,Nato AQ,Bernier R,et al.Whole exome sequencing in extended families with autism spectrum disorder implicates four candidate genes[J].Human Genetics,2015,134(10):1055-1068.
[3]Redies C,Vanhalst K,Roy FV.δ-protocadherins:Unique structures and functions[J].Cellular & Molecular Life Sciences,2005,62(23):2840-2852.
[4]Patel SD,Ciatto C,Chen CP,et al.Type II cadherin ectodomain structures:Implications for classical cadherin specificity[J].Cell,2006,124(6):1255-1268.
[5]Dilling C,Roewer N,Frster CY,et al.Multiple protocadherins are expressed in brain microvascular endothelial cells and might play a role in tight junction protein regulation[J].J Cereb Blood Flow Metab,2017,37(10):3391-3400.
[6] Halem HA,Cherry JA,Baum MJ.Vomeronasal neuroepithelium and forebrain Fos responses to male pheromones in male and female mice[J].J Neurobiol,2015,39(2):249-263.
[7] Ke C,Li C,Huang X,et al.Protocadherin20 promotes excitatory synaptogenesis in dorsal horn and contributes tobone cancer pain [J].Neurpharmacology,2013(75):181-190.
[8] Liu J,Ji W,Sun S,et al.The PP2A-Aβ gene is regulated by multiple transcriptional factors including Ets-1,SP1/SP3,and RXRα/β[J].Curr Mol Med,2012,12(8):982-994.
[9] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Ca Cancer J Clin,2016,66(2):115-132.
[10] LU Shun,YU Yongfeng,JI Wenxiang.2015 guidelines for diagnosis and treatment of lung cancer:Consensus and controversy [J].PLA Medical Journal,2016,41(1):1-6.[陆舜,虞永峰,纪文翔.2015年肺癌诊疗指南:共识和争议[J].解放军医学杂志,2016,41(1):1-6.]
[11] Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].A Cancer Journal for Clinicians,2018,60(5):277-300.
[12]Ahmad I,Rao DN.Chemistry and biology of DNA methyltransferases[J].Crc Critical Reviews in Biochemistry,1996,31(5-6):361-380.
[13]Herman JG,Latif F,Weng Y,et al.Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma[J].Proc Natl Acad Sci USA,1994,91(21):9700-9704.
[14]Imoto I,Izumi H,Yokoi S,et al.Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers[J].Cancer Research,2006,66(9):4617-4626.
[15] MA Rongfen,CHEN Qiuying,LIU Yanfen.Correlation between expression levels of PCDH20,VEGF protein and HE4 and clinicopathology in lung cancer patients[J].Hebei Pharmaceutical,2018,40(09):1343-1347.[马荣芬,陈秋英,刘艳芬.肺癌患者PCDH20、VEGF蛋白和HE4表达水平与临床病理的相关性研究[J].河北医药,2018,40(09):1343-1347.]
[16]Zhao Yu,Liu Zhanyan,Zhu Feng,et al.Correlation of PCDH20,VEGF protein and clinical pathological indicators in patients with lung cancer[J].Laboratory Medicine & Clinic,2016,13(22):3196-3198.
[17] Zhao L,Fong AHW,Liu N,et al.Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNA-based prognostic model for distant metastasis[J].Journal of Biomedical Science,2018,25(1):16.
[18]Long Biaoli.Methylation and function of PCDH20 gene in nasopharyngeal carcinoma[D].Chongqing:Chongqing Medical University,2013.[龙表利.PCDH20基因在鼻咽癌中的甲基化及功能[D].重庆:重庆医科大学,2013.]
[19] Ooft ML,van Ipenburg J,van Loo R,et al.Molecular profile of nasopharyngeal carcinoma:Analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification[J].J Clin Pathol,2018,71(4):351-359.
[20]Tao C,Biaoli L,Guosheng R,et al.Protocadherin20 acts as a tumor suppressor gene:Epigenetic inactivation in nasopharyngeal carcinoma[J].Journal of Cellular Biochemistry,2015,116(8):1766-1775.
[21] Li S,Han Z,Zhao N,et al.Inhibition of DNMT suppresses the stemness of colorectal cancer cells through down-regulating Wnt signaling pathway[J].Cellular Signalling,2018(47):79-87.
[22]Shan M,Su Y,Kang W,et al.Aberrant expression and functions of protocadherins in human malignant tumors[J].Tumour Biology,2016,37(10):12969-12981.
[23] Chen J,Shen Z,Deng H,et al.Long non-coding RNA biomarker for human laryngeal squamous cell carcinoma prognosis[J].Gene,2018(671):96-102.
[24] GONG Zhitao.Expression of PCDH20 gene in laryngeal cancer and its correlation with prognosis of laryngeal cancer[D].Chongqing:Chongqing Medical University,2016.[龚志涛.PCDH20基因在喉癌中的表达及与喉癌预后的相关性研究[D].重庆:重庆医科大学,2016.]
[25]LIU Y,YUAN DH,AN T,et al.Research progress on risk factors of colorectal cancer[J].Shaanxi Journal of Medicine,2016,45 (11):1561-1562.[刘琰,袁东红,安太,等.大肠癌发病危险因素研究进展[J].陕西医学杂志,2016,45(11):1561-1562.]
[26] GENG SM.Role of PCDH20 gene in the development of colorectal cancer[D].Zhejiang:Zhejiang University,2011.[耿淑敏.PCDH20基因在大肠癌发生发展中的作用研究[D].浙江:浙江大学,2011.]
[27]Magistri P,Tarantino G,Ballarin R,et al.The evolving role of local treatments for HCC in the third millennium[J].Anticancer Research,2017,37(2):389-401.
[28] Taciak B,Pruszynska I,Kiraga L,et al.Wnt signaling pathway in development and cancer[J].Journal of Physiology & Pharmacology,2018,69(2):185-196.
[29] Zeng T,Guo X,Liu J.Negative correlation based gene markers identification in integrative gene expression data[J].International Journal of Data Mining & Bioinformatics,2014,10(1):1-17.
[30]Ying J,Li H,Seng TJ,et al.Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal,esophageal and multiple other carcinomas with frequent methylation[J].Oncogene,2005,25(7):1070-1080.
[31]Rui Ose,Toshihide Yanagawa,Shun Ikeda,et al.PCDH24-induced contact inhibition involves downregulation of β-catenin signaling[J].Molecular Oncology,2009,3(1):54-66.
[32]Kim SY,Yasuda S,Tanaka H,et al.Non-clustered protocadherin[J].Cell Adhesion & Migration,2011,5(2):97-105.
[33]Kim SY,Chung HS,Sun W,et al.Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain[J].Neuroscience,2007,147(4):996-1021.


更新日期/Last Update: 1900-01-01